Comprehensive Stock Comparison
Compare Fortress Biotech, Inc. (FBIO) vs Immunome, Inc. (IMNM) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | FBIO | -31.8% revenue growth vs IMNM's -35.5% |
| Quality / Margins | FBIO | 6.4% net margin vs IMNM's -23.0% |
| Stability / Safety | FBIO | Beta 0.65 vs IMNM's 1.42 |
| Dividends | FBIO | 1.0% yield; IMNM pays no meaningful dividend |
| Momentum (1Y) | IMNM | +132.6% vs FBIO's +117.8% |
| Efficiency (ROA) | FBIO | 2.2% ROA vs IMNM's -74.4%, ROIC -6.3% vs -7.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Fortress Biotech is a biopharmaceutical company that develops and commercializes pharmaceutical products across multiple therapeutic areas. It generates revenue primarily through sales of its marketed dermatology products — including treatments for acne and skin conditions — supplemented by milestone payments and potential future royalties from its extensive pipeline of late-stage and early-stage drug candidates. The company's key advantage lies in its diversified portfolio approach, which spreads risk across multiple development programs while leveraging partnerships to fund research and development.
Immunome is a biopharmaceutical company that discovers and develops antibody therapeutics for cancer and infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — with no commercial products yet — as it advances its pipeline of antibody candidates. The company's key advantage lies in its proprietary discovery platform that identifies human antibodies from patient immune responses, potentially yielding more effective and safer therapeutic candidates.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
FBIO leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). IMNM leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
FBIO is the larger business by revenue, generating $62M annually — 6.4x IMNM's $10M. FBIO is the more profitable business, keeping 6.4% of every revenue dollar as net income compared to IMNM's -23.0%. On growth, FBIO holds the edge at +20.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FBIOFortress Biotech,… | IMNMImmunome, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $62M | $10M |
| EBITDAEarnings before interest/tax | -$88M | -$232M |
| Net IncomeAfter-tax profit | $4M | -$223M |
| Free Cash FlowCash after capex | -$66M | -$192M |
| Gross MarginGross profit ÷ Revenue | +65.8% | -4.2% |
| Operating MarginEBIT ÷ Revenue | -149.2% | -24.2% |
| Net MarginNet income ÷ Revenue | +6.4% | -23.0% |
| FCF MarginFCF ÷ Revenue | -106.2% | -19.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +20.5% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +114.5% | +16.7% |
Valuation Metrics
| Metric | FBIOFortress Biotech,… | IMNMImmunome, Inc. |
|---|---|---|
| Market CapShares × price | $95M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $114M | $1.9B |
| Trailing P/EPrice ÷ TTM EPS | -1.27x | -4.37x |
| Forward P/EPrice ÷ next-FY EPS est. | 342.00x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.65x | 221.74x |
| Price / BookPrice ÷ Book value/share | — | 7.08x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
FBIO delivers a 6.1% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-84 for IMNM.
| Metric | FBIOFortress Biotech,… | IMNMImmunome, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +6.1% | -84.4% |
| ROA (TTM)Return on assets | +2.2% | -74.4% |
| ROICReturn on invested capital | -6.3% | -7.0% |
| ROCEReturn on capital employed | -142.0% | -195.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | $19M | -$139M |
| Cash & Equiv.Liquid assets | $57M | $143M |
| Total DebtShort + long-term debt | $76M | $5M |
| Interest CoverageEBIT ÷ Interest expense | -4.25x | — |
Total Returns (with DRIP)
A $10,000 investment in IMNM five years ago would be worth $5,472 today (with dividends reinvested), compared to $588 for FBIO. Over the past 12 months, IMNM leads with a +132.6% total return vs FBIO's +117.8%. The 3-year compound annual growth rate (CAGR) favors IMNM at 68.5% vs FBIO's -33.3% — a key indicator of consistent wealth creation.
| Metric | FBIOFortress Biotech,… | IMNMImmunome, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -15.1% | +5.0% |
| 1-Year ReturnPast 12 months | +117.8% | +132.6% |
| 3-Year ReturnCumulative with dividends | -70.4% | +378.3% |
| 5-Year ReturnCumulative with dividends | -94.1% | -45.3% |
| 10-Year ReturnCumulative with dividends | -92.0% | +62.5% |
| CAGR (3Y)Annualised 3-year return | -33.3% | +68.5% |
Risk & Volatility
FBIO is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than IMNM's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMNM currently trades 79.1% from its 52-week high vs FBIO's 75.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FBIOFortress Biotech,… | IMNMImmunome, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.65x | 1.42x |
| 52-Week HighHighest price in past year | $4.53 | $27.65 |
| 52-Week LowLowest price in past year | $1.33 | $5.15 |
| % of 52W HighCurrent price vs 52-week peak | +75.5% | +79.1% |
| RSI (14)Momentum oscillator 0–100 | 51.9 | 42.9 |
| Avg Volume (50D)Average daily shares traded | 729K | 1.5M |
Analyst Outlook
Wall Street rates FBIO as "Buy" and IMNM as "Buy". FBIO is the only dividend payer here at 0.98% yield — a key consideration for income-focused portfolios.
| Metric | FBIOFortress Biotech,… | IMNMImmunome, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $35.29 |
| # AnalystsCovering analysts | 6 | 9 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.03 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 20 | Feb 26 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | 100 | 9.46 | -90.5% |
| Immunome, Inc. (IMNM) | 81.64 | 194.35 | +138.1% |
Immunome, Inc. (IMNM) returned -45% over 5 years vs Fortress Biotech, I… (FBIO)'s -94%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | $863000.00 | $58M | +6583.1% |
| Immunome, Inc. (IMNM) | $0.00 | $9M | — |
Fortress Biotech, Inc.'s revenue grew from $1M (2015) to $58M (2024) — a 59.5% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | -56.1% | -79.8% | -42.1% |
| Immunome, Inc. (IMNM) | -7.6% | -32.4% | -325.3% |
Fortress Biotech, Inc.'s net margin went from -56% (2015) to -80% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Fortress Biotech, I… (FBIO) | -18.56 | -2.69 | +85.5% |
| Immunome, Inc. (IMNM) | -7.18 | -5 | +30.4% |
Fortress Biotech, Inc.'s EPS grew from $-18.56 (2015) to $-2.69 (2024).
Chart 5Free Cash Flow — 5 Years
Fortress Biotech, Inc. generated $-95M FCF in 2024 (+28% vs 2021). Immunome, Inc. generated $-164M FCF in 2024 (-798% vs 2021).
FBIO vs IMNM: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is FBIO or IMNM a better buy right now?
Analysts rate Fortress Biotech, Inc. (FBIO) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FBIO or IMNM?
Over the past 5 years, Immunome, Inc. (IMNM) delivered a total return of -45.3%, compared to -94.1% for Fortress Biotech, Inc. (FBIO). A $10,000 investment in IMNM five years ago would be worth approximately $5K today (assuming dividends reinvested). Over 10 years, the gap is even starker: IMNM returned +62.5% versus FBIO's -92.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FBIO or IMNM?
By beta (market sensitivity over 5 years), Fortress Biotech, Inc. (FBIO) is the lower-risk stock at 0.65β versus Immunome, Inc.'s 1.42β — meaning IMNM is approximately 119% more volatile than FBIO relative to the S&P 500.
04Which has better profit margins — FBIO or IMNM?
Fortress Biotech, Inc. (FBIO) is the more profitable company, earning -79.8% net margin versus -32.4% for Immunome, Inc. — meaning it keeps -79.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FBIO leads at -191.4% versus -33.8% for IMNM. At the gross margin level — before operating expenses — IMNM leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — FBIO or IMNM?
In this comparison, FBIO (1.0% yield) pays a dividend. IMNM does not pay a meaningful dividend and should not be held primarily for income.
06Is FBIO or IMNM better for a retirement portfolio?
For long-horizon retirement investors, Fortress Biotech, Inc. (FBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 1.0% yield). Both have compounded well over 10 years (FBIO: -92.0%, IMNM: +62.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between FBIO and IMNM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. FBIO pays a dividend while IMNM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.